BOSTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a ...

Jnana Therapeutics is hitting early-stage momentum, adding additional validation in the form of new cash and a fresh Big Pharma collaboration just as its lead metabolic disease asset launches into ...

Jnana Therapeutics announced Tuesday that it raised $107 million in series C financing, more than doubling the $100 million it raised in its previous two rounds. Jnana also struck its second drug ...

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets ...

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push ...

TOKYO, Aug 1 (Reuters) - Japan's Otsuka Pharmaceutical (4578.T), opens new tab said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug ...